Stanford V is a chemotherapy regimen currently in clinical trials at Stanford Medical Center for Hodgkin's Lymphoma / Disease. Seven different chemotherapy drugs are administered over a shorter period of time, but more frequently, than standard chemotherapy regimens such as MOPP or ABVD. It is believed that this regimen will prove to be at least as effective as ABVD, while being better tolerated and having fewer long term side effects.
The drugs in the regimen:
• Mechlorethamine (Mustargen) by vein once every 4 weeks
• Doxorubicin (Adriamycin) by vein every odd week
• Vinblastine (Velban) by vein every odd week
• Vincristine (Oncovin) by vein every even week
• Bleomycin (Blenoxane) by vein every even week
• Etoposide (VP-16) by vein 2 days in a row weeks 3, 7, 11
• Prednisone by mouth every other day
There are also other drugs prescribed to help with side effects and to prevent mouth sores and infection.
Effectiveness:
In trials from May 1989 to August 1995, 94 previously untreated patients with Hodgkin's disease (28 stage II bulky disease, and 66 stage III or IV) received Stanford V chemotherapy for 12 weeks with and without radiation therapy. With a median follow-up of 3 years, the actuarial 6-year survival was 93% and the freedom from progression 89%. There had been no relapses or deaths among the 28 patients with stage II bulky mediastinal disease. Eight relapses and three deaths occurred in the group of 66 patients with stage III-IV disease. Lower cumulative exposure to alkylating agents,
doxorubicin,
bleomycin and limited use of
radiation is expected to improved the prospects for fertility and decrease the risks for secondary cancers and hear t problems.
Side Effects:
See information on individual chemotherapy agents for side effects. Again the trial organizers hope that side effects are reduced compared to
ABVD.
Sponsored Links
Resources
Study Center(s):
Stanford University Medical Center
Current Study (1/2004)
Stanford Hospital and Clinics
Links for more information on Stanford V:
NCBI PubMed: J Clin Oncol 2002 Feb 1;20(3):607-9 Horning SJ et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial
Mike Lach's Stanford V Page
Li's Pages - Stanford V
Experiences
Mike Lach's Hodgkins Page
Send Yours In
Related Articles
For more information on Adult Hodgkin's Disease, please see the following pages:
Hodgkin's Disease: Chemotherapy
Hodgkin's Disease: Treatment
Hodgkin's Disease: Resources
Hodgkin's Disease: Diagnosis
Hodgkin's Disease (Main Page)
Bone Marrow / Peripheral Blood Stem Cell Transplants
Other pages you may want to visit:
Lymphoma Information Network
Childhood Hodgkin's Disease Information Pages
Books
Books on Lymphoma Treatment including chemotherapy
